Showing 5331-5340 of 6634 results for "".
- University of Arkansas Researcher Scores $1.6M NIH Grant for Research on Chronic Skin Woundshttps://practicaldermatology.com/news/puniversity-of-arkansas-researcher-scores-16m-nih-grant-for-research-on-chronic-skin-wounds/2460976/University of Arkansas biomedical engineering professor Kyle Quinn received a four-year, $1.6 million grant from the National Institutes of Health to develop non-invasive, real-time “optical biopsies” of chronic skin wounds. The goal is to provide digital histopathology imag
- CeraVe Releases New "Think Ceramides!" Digital Campaignhttps://practicaldermatology.com/news/cerave-releases-new-think-ceramides-digital-campaign/2460975/In support of National Healthy Skin Month this November, CeraVe announces is launching its new "Think Ceramides!" digital campaign. The brand's latest omni-channel initiative focuses on the importance and benefits of ceramides, which are included within all CeraVe pr
- Sun Pharma’s WINLEVI for Acne Now Availablehttps://practicaldermatology.com/news/sun-pharmas-winlevi-for-acne-now-available/2460974/WINLEVI (clascoterone) cream 1% is now available the US, according to Sun Pharmaceutical Industries Limited. A first-in-class topical androgen receptor inhibitor, WINLEVI was approved by FDA in August 2020 for the topical treatment of acne vulgaris in patients 12 yea
- Dupixent Reduces Itch, Clears Skin in Prurigo Nodularis Phase 3 Trialhttps://practicaldermatology.com/news/dupixent-reduces-itch-clears-skin-in-prurigo-nodularis-phase-3-trial/2460969/Data from a pivotal Phase 3 trial show that Dupixent® (dupilumab) reduced itch and led to higher rates of skin clearance than placebo among adults with uncontrolled prurigo nodularis. In the Phase 3 PRIME2 trial, 37 percent of Dupixent
- Can Applying an Electric Field to the Skin Cure Fibrosis?https://practicaldermatology.com/news/can-applying-an-electric-field-to-the-skin-cure-fibrosis/2460965/Applying an electric field to the skin could cure skin fibrosis by reducing overly high collagen levels, a new study suggests. Published in the Journal of Investigative Dermatology, the results open new therapeutic perspectives for the topical treatment of skin fibrosis charact
- Potential Melanoma Treatment Breakthrough: Is KDM5B the Key?https://practicaldermatology.com/news/potential-melanoma-treatment-breakthrough-is-kdm5b-the-key/2460964/The enzyme KDM5B may suppress anti-melanoma immunity, and these findings could help lead to the development of a new treatment strategy to benefit patients with melanoma and other cancers, according to a new study out of the Yale Cancer Center in New Haven, Conn. The research
- FDA Approves Cyltezo as First Interchangeable Biosimilar with Humirahttps://practicaldermatology.com/news/fda-approves-cyltezo-as-first-interchangeable-biosimilar-with-humira/2460957/The FDA approved the supplemental Biologics License Application (sBLA) for Boehringer Ingelheim's Cyltezo (adalimumab-adbm) as the first Interchangeable biosimilar with Humira (adalimumab). The FDA originally approved Cyltezo in 2017 for the treatment of multiple chronic inflammatory diseases
- Vivacare Partnership with Asthma and Allergy Network Provides Professional Digital Patient Education Servicehttps://practicaldermatology.com/news/vivacare-partnership-with-asthma-and-allergy-network-provides-professional-digital-patient-education-service/2460956/Through a new partnership, Vivacare and the Asthma and Allergy Network (AAN) will provide a digital patient education service to Vivacare’s 18,000 professional members, including allergists, dermatologists, pediatricians and primary care providers. Personalized “P
- Janssen Seeks FDA Nod for Stelara in Juvenile PsAhttps://practicaldermatology.com/news/janssen-seeks-fda-nod-for-stelara-in-juvenile-psa/2460949/Janssen is seeking expanded approval of Stelara (ustekinumab) for pediatric patients aged five and older with juvenile psoriatic arthritis (jPsA). The company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA). The filing is
- Topline Phase 2b Data Promising for Timber's Topical Isotretinoin in CIhttps://practicaldermatology.com/news/topline-phase-2b-data-promising-for-timbers-topical-isotretinoin-in-ci/2460946/Top-line data from Timber Pharmaceuticals’ Phase 2b CONTROL study show “clinically meaningful efficacy with a favorable safety profile” for investigational topical isotretinoin, says the company’s Chairman and CEO John Koconis. TMB-001 is formulated using